REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Ziff, M. [1 ]
Cheesman, S. [1 ]
Kyriakou, C. [1 ]
Mehta, A. [1 ]
Papanikolaou, X. [1 ]
Rabin, N. [1 ]
Wechalekar, A. [1 ]
Yong, K. [1 ]
Popat, R. [1 ]
机构：
[1] Univ Coll London Hosp NHS Fdn Trust, London, England
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1975
引用
收藏
页码：786 / 787
页数：2
相关论文
共 50 条
  • [1] Real World Use of Ixazomib With Lenalidomide and Dexamethasone for Patients With Relapsed Multiple Myeloma
    Lawson, Gabrielle
    Ziff, Monica
    De-Silva, Dunnya
    Cheesman, Simon
    Kyriakou, Charalampia
    Mehta, Atul
    Mahmood, Shameem
    Papanikolaou, Xenofon
    Rabin, Neil
    Sachchithanantham, Sajitha
    Sive, Jonathan
    Wechalekar, Ashutosh
    Yong, Kwee
    Popat, Rakesh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E264 - E264
  • [2] Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma
    Minarik, Jiri
    Pika, Tomas
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Mistrik, Martin
    Brozova, Lucie
    Krhovska, Petra
    Machalkova, Katerina
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Capkova, Lenka
    Sykora, Michal
    Kessler, Petr
    Stejskal, Lukas
    Heindorfer, Adriana
    Ullrychova, Jana
    Maisnar, Vladimir
    Hajek, Roman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E271 - E272
  • [3] Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma
    Lee, Ji Hyun
    Kim, Sung-Hyun
    Kim, Hye Ryeon
    Min, Chang-Ki
    Lee, Je-Jung
    Shin, Ho-Jin
    Jo, Jae-Cheol
    Lee, Ji Yun
    Moon, Joon Ho
    Kim, Kihyun
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (02) : 225 - 235
  • [4] Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma
    Sokol, Juraj
    Guman, Tomas
    Chudej, Juraj
    Hlebaskova, Monika
    Stecova, Natalia
    Valekova, Lubica
    Kucerikova, Monika
    Stasko, Jan
    ANNALS OF HEMATOLOGY, 2022, 101 (01) : 81 - 89
  • [5] Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma
    Ji Hyun Lee
    Sung-Hyun Kim
    Hye Ryeon Kim
    Chang-Ki Min
    Je-Jung Lee
    Ho-Jin Shin
    Jae-Cheol Jo
    Ji Yun Lee
    Joon Ho Moon
    Kihyun Kim
    International Journal of Hematology, 2023, 117 : 225 - 235
  • [6] Ixazomib, lenalidomide, and dexamethasone combination in “real-world” clinical practice in patients with relapsed/refractory multiple myeloma
    Juraj Sokol
    Tomas Guman
    Juraj Chudej
    Monika Hlebaskova
    Natalia Stecova
    Lubica Valekova
    Monika Kucerikova
    Jan Stasko
    Annals of Hematology, 2022, 101 : 81 - 89
  • [7] Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
    Terpos, Evangelos
    Ramasamy, Karthik
    Maouche, Nadjoua
    Minarik, Jiri
    Ntanasis-Stathopoulos, Ioannis
    Katodritou, Eirini
    Jenner, Matthew W.
    Plonkova, Hana
    Gavriatopoulou, Maria
    Vallance, Grant D.
    Pika, Tomas
    Kotsopoulou, Maria
    Kothari, Jaimal
    Jelinek, Tomas
    Kastritis, Efstathios
    Aitchison, Robin
    Dimopoulos, Meletios A.
    Zomas, Athanasios
    Hajek, Roman
    ANNALS OF HEMATOLOGY, 2020, 99 (05) : 1049 - 1061
  • [8] Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
    Evangelos Terpos
    Karthik Ramasamy
    Nadjoua Maouche
    Jiri Minarik
    Ioannis Ntanasis-Stathopoulos
    Eirini Katodritou
    Matthew W. Jenner
    Hana Plonkova
    Maria Gavriatopoulou
    Grant D. Vallance
    Tomas Pika
    Maria Kotsopoulou
    Jaimal Kothari
    Tomas Jelinek
    Efstathios Kastritis
    Robin Aitchison
    Meletios A. Dimopoulos
    Athanasios Zomas
    Roman Hajek
    Annals of Hematology, 2020, 99 : 1049 - 1061
  • [9] Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
    M. Macro
    C. Hulin
    L. Vincent
    A. Charvet-Rumpler
    L. Benboubker
    C. Calmettes
    A.-M. Stoppa
    K. Laribi
    L. Clement-Filliatre
    H. Zerazhi
    F. Honeyman
    V. Richez
    F. Maloisel
    L. Karlin
    J. Barrak
    C. Chouaid
    X. Leleu
    Annals of Hematology, 2023, 102 : 2137 - 2151
  • [10] Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
    Macro, M.
    Hulin, C.
    Vincent, L.
    Charvet-Rumpler, A.
    Benboubker, L.
    Calmettes, C.
    Stoppa, A. -m.
    Laribi, K.
    Clement-Filliatre, L.
    Zerazhi, H.
    Honeyman, F.
    Richez, V.
    Maloisel, F.
    Karlin, L.
    Barrak, J.
    Chouaid, C.
    Leleu, X.
    ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2137 - 2151
12345